1. Home
  2. PPBT vs RVYL Comparison

PPBT vs RVYL Comparison

Compare PPBT & RVYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PPBT
  • RVYL
  • Stock Information
  • Founded
  • PPBT 2010
  • RVYL 2007
  • Country
  • PPBT Israel
  • RVYL United States
  • Employees
  • PPBT N/A
  • RVYL N/A
  • Industry
  • PPBT Biotechnology: Pharmaceutical Preparations
  • RVYL Professional Services
  • Sector
  • PPBT Health Care
  • RVYL Consumer Discretionary
  • Exchange
  • PPBT Nasdaq
  • RVYL Nasdaq
  • Market Cap
  • PPBT 7.1M
  • RVYL 8.2M
  • IPO Year
  • PPBT N/A
  • RVYL N/A
  • Fundamental
  • Price
  • PPBT $2.73
  • RVYL $0.98
  • Analyst Decision
  • PPBT Strong Buy
  • RVYL Hold
  • Analyst Count
  • PPBT 1
  • RVYL 1
  • Target Price
  • PPBT $33.00
  • RVYL N/A
  • AVG Volume (30 Days)
  • PPBT 16.2K
  • RVYL 40.5K
  • Earning Date
  • PPBT 05-20-2025
  • RVYL 05-13-2025
  • Dividend Yield
  • PPBT N/A
  • RVYL N/A
  • EPS Growth
  • PPBT N/A
  • RVYL N/A
  • EPS
  • PPBT N/A
  • RVYL N/A
  • Revenue
  • PPBT N/A
  • RVYL $55,998,000.00
  • Revenue This Year
  • PPBT N/A
  • RVYL $36.61
  • Revenue Next Year
  • PPBT N/A
  • RVYL $26.67
  • P/E Ratio
  • PPBT N/A
  • RVYL N/A
  • Revenue Growth
  • PPBT N/A
  • RVYL N/A
  • 52 Week Low
  • PPBT $2.00
  • RVYL $0.69
  • 52 Week High
  • PPBT $20.60
  • RVYL $2.40
  • Technical
  • Relative Strength Index (RSI)
  • PPBT 51.95
  • RVYL 51.88
  • Support Level
  • PPBT $2.67
  • RVYL $0.94
  • Resistance Level
  • PPBT $2.75
  • RVYL $1.18
  • Average True Range (ATR)
  • PPBT 0.21
  • RVYL 0.10
  • MACD
  • PPBT 0.04
  • RVYL 0.01
  • Stochastic Oscillator
  • PPBT 67.19
  • RVYL 80.65

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

About RVYL Ryvyl Inc.

Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.

Share on Social Networks: